UNITY Biotechnology Inc [UBX]

South san francisco, calif., dec. 22, 2021 (globe newswire) -- unity biotechnology, inc. (“unity”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from december 7, 2021, through december 21, 2021, the compensation committee of the board of directors (the “board”) granted a new employee a stock-based award covering an aggregate of 4,500 shares of unity common stock, including options to purchase an aggregate of 4,500 shares of unity common stock. the stock-based award was granted pursuant to the unity 2020 employment inducement incentive plan, as amended, which was approved by the board in march 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with unity in accordance with nasdaq stock market rule 5635(c)(4).

South san francisco, calif., dec. 20, 2021 (globe newswire) -- unity biotechnology, inc. (“unity”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced it has signed an exclusive agreement licensing its Α-klotho asset to jocasta neuroscience, inc. for development and commercialization.

Patients with diabetic macular edema in higher dose cohorts showed a mean bcva gain of approximately 10 etdrs letters sustained through 24 weeks after a single intravitreal injection

South san francisco, calif., nov. 03, 2021 (globe newswire) -- unity biotechnology, inc. (“unity”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from october 19, 2021, through november 2, 2021, the compensation committee of the board of directors (the “board”) granted two new employees stock-based awards covering an aggregate of 190,000 shares of unity common stock, including options to purchase an aggregate of 160,000 shares of unity common stock and one grant consisting of 30,000 restricted stock units which will vest on the one-year anniversary of the vesting commencement date. the stock-based awards were granted pursuant to the unity 2020 employment inducement incentive plan, as amended, which was approved by the board in march 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with unity in accordance with nasdaq stock market rule 5635(c)(4).

South san francisco, calif., oct. 06, 2021 (globe newswire) -- unity biotechnology, inc. (“unity”) [nasdaq: ubx], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from september 21, 2021, through october 5, 2021, the compensation committee of the board of directors (the “board”) granted 4 new employees stock-based awards covering an aggregate of 138,500 shares of unity common stock, including options to purchase an aggregate of 138,500 shares of unity common stock. the stock-based awards were granted pursuant to the unity 2020 employment inducement incentive plan, as amended, which was approved by the board in march 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with unity in accordance with nasdaq stock market rule 5635(c)(4).

Mizuho upgraded Unity Biotechnology Inc (NASDAQ: UBX) to Buy from Neutral with a price target of $7, up from $5 after Unity announced longer-term Phase 1 data for UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD). Analyst Salim Syed expects some investor sentiment shift to begin at this point for this "underfollowed" stock.

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from September 21, 2021, through October 5, 2021, the Compensation Committee of the Board of Directors (the “Board”) granted 4 new employees stock-based awards covering an aggregate of 138,500 shares of UNITY common stock, including options to purchase an aggregate of 138,500 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and wet age-related macular degeneration (AMD), for whom anti-VEGF therapy was no longer considered beneficial.  The data show strong and sustained responses following a single injection of UBX1325.

16 th Annual Citi BioPharma Conference on September 8-10, 2021

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from August 3, 2021, through August 17, 2021, the Compensation Committee of the Board of Directors (the “Board”) granted 2 new employees stock-based awards covering an aggregate of 49,000 shares of UNITY common stock, including options to purchase an aggregate of 49,000 shares of UNITY common stock. The stock-based awards were granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4).

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will present at the upcoming H.C. Wainwright Ophthalmology Virtual Conference.

UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD)

SUZHOU, China, and ROCKVILLE, Md., July 28, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its global licensee, UNITY Biotechnology, Inc. ("UNITY", NASDAQ:UBX), has reported encouraging data from a Phase I clinical study of UBX1325, an investigational Bcl-xL inhibiting compound, in patients with certain advanced vascular eye diseases, and has already dosed the first patient in the subsequent Phase IIa clinical study.

I recently covered Unity's transition away from its failed osteoarthritis program to its ophthalmology program focused on retinal diseases.

UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325